Skip to navigation Skip to content
  • The Cancer Letter on Facebook
  • The Cancer Letter on Twitter
  • The Cancer Letter on LinkedIn

The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
  • SUBSCRIBE
  • Login
  • SUBSCRIBE
  • Login
The Cancer Letter
Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
Clinical Roundup

OSUCCC—James study suggests a way to re-energize tired T cells when treating cancer, viral infections

January 27, 2023
Vol.49 No.04
Clinical Roundup

Multicenter study reveals worse outcomes in understudied breast cancer

December 02, 2022
Vol.48 No.43
In Brief

Miami Cancer Institute, ChristianaCare, Ochsner, OSUCCC – James, Massey named ACCC 2022 Innovator Award winners

October 21, 2022
Vol.48 No.38
Clinical RoundupFree

OSUCCC – James study identifies molecular factors driving melanoma development

July 01, 2022
Vol.48 No.26
Clinical Roundup

OSUCCC-James study: Selective dopamine D2 receptor agonists may curb cancer growth, with fewer side effects

May 27, 2022
Vol.48 No.21
Clinical Roundup

OSUCCC program aims to reduce inequities in colon cancer rates by mailing at-home screening kits to Black patients

March 25, 2022
Vol.48 No.12
Clinical Roundup

OSUCCC – James study highlights impact of intersecting identities in cancer risk

March 18, 2022
Vol.48 No.11

Posts navigation

Previous123

Trending Stories

  • Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
  • Michael Bishop, Nobel-winning cancer researcher, dies at 90
  • A new working group will conduct site visits and advise NCAB and NCI director on cancer center grants
  • Roy Herbst named director at Dartmouth Cancer Center
  • In the era of immunotherapy, response rate alone fails to predict true patient benefit
    Regulators must adapt
  • FDA issues warning letter to ImmunityBio over misleading claims about cancer drug

ABOUT
ABOUT
About The Cancer Letter
Accessibility Statement
Our Contributors
Editorial policies
Store
SUBSCRIPTIONS
SUBSCRIPTIONS
Our readers
Pricing
News alerts
About IP login
Job board
CONTACT
CONTACT
Contact us
Submission guidelines
Advertise
Careers
SEE ALSO
Cancer History Project
The Cancer Letter
Copyright © 2026 The Cancer Letter Inc. All rights reserved.
Privacy Policy
Terms & Conditions
FOLLOW US
Instagram
Twitter
LinkedIn
Facebook
Vimeo
Scroll to top
Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.
SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.
LOGINSUBSCRIBE NOW
SEARCH DATE
SEARCH TEXT
      Cancel
      OK
      Cancel
      OK
      Delete Account
      Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below
      No

      Never miss an issue!

      Get alerts for our award-winning coverage in your inbox.

      Login

       
      Forgot Password?

      Site license subscribers:
      Log in with your IP | Register a sponsored account